<DOC>
	<DOCNO>NCT00000983</DOCNO>
	<brief_summary>To evaluate compare difference tolerance side effect associate two different dosage zidovudine ( AZT ) use treat child HIV infection . Other goal evaluate compare degree change neurodevelopmental disease determine whether difference rate degree toxicity associate one versus dosage . AZT show decrease death rate frequency opportunistic infection certain adult patient symptomatic HIV infection . Thus , likely symptomatic HIV infect child may also benefit AZT . Studies safety pharmacokinetics ( blood level ) child indicate AZT give child dos tolerate assumed therapeutic . Those currently take care infected child longer feel ethical conduct AZT/placebo ( inactive substance ) trial . In addition , give information learn study adult patient show effectiveness AZT low dos , experience equivalent low dose child need study .</brief_summary>
	<brief_title>The Safety Different Dose Levels Zidovudine HIV-Infected Children</brief_title>
	<detailed_description>AZT show decrease death rate frequency opportunistic infection certain adult patient symptomatic HIV infection . Thus , likely symptomatic HIV infect child may also benefit AZT . Studies safety pharmacokinetics ( blood level ) child indicate AZT give child dos tolerate assumed therapeutic . Those currently take care infected child longer feel ethical conduct AZT/placebo ( inactive substance ) trial . In addition , give information learn study adult patient show effectiveness AZT low dos , experience equivalent low dose child need study . All participant randomize receive AZT 1 2 dos . Patients stratify accord whether CD4 cell count &gt; &lt; 500 cells/mm3 well whether symptom mild moderate patient lymphocytic interstitial pneumonitis ( LIP ) . Medication dispense every week first 8 week monthly week 104 , either monthly every 3 month . Safety effectiveness treatment program evaluate 6-month interval ass whether appropriate continue study originally design . Patients evaluate every 2 week first 8 week , monthly week 104 , every 3 month week 208 , every 6 month thereafter .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : AMENDED : 031991 Prophylaxis PCP recommend accord current practice guideline . As per publish recommendation , primary prophylaxis TMP / SMX MTW basis encourage . Allowed : Immunoglobulin therapy single dose exposure prophylaxis child hypogammaglobulinemia . Trimethoprim / sulfamethoxazole ( TMP / SMX ) parenteral aerosolize pentamidine prophylaxis Pneumocystis carinii pneumonia child AIDS and/or CD4+ count = &lt; 500 cells/mm3 . Systemic ketoconazole acyclovir , oral nystatin acute therapy . Aerosol ribavirin shortterm treatment acute respiratory syncytial virus ( RSV ) . AMENDED : 9/17/90 enrollment limit child &lt; 6 year age . Original design : Patients must follow : Parent guardian available give write informed consent . Laboratory evidence HIV infection . Children &lt; 15 month age , CD4+ cell count &gt; 500 cells/mm3 , think acquire HIV perinatal transmission whose laboratory evidence HIV infection positive antibody test , must also one laboratory criterion describe Disease Status AND one disease criterion require child &gt; 15 month old CD4+ cell count &gt; 500 cells/mm3 . Prior Medication : Allowed : Aerosol ribavirin . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Previous AIDSdefining opportunistic infection neoplasm specify CDC surveillance criterion AIDS . Previous unexplained recurrent , serious bacterial infection ( two within 2year period ) include sepsis , meningitis , pneumonia , abscess internal organ , bone/joint infection cause Haemophilus , Streptococcus , pyogenic bacteria . Qualifying entrance criterion zidovudine ( AZT ) + gammaglobulin ( ACTG 051 ) . Encephalopathy . Failure thrive ( defined child cross two percentile line growth chart child &lt; fifth percentile follow curve ) and/or oral candidiasis least 2 month despite appropriate topical therapy . Lymphocytic interstitial pneumonitis ( LIP ) steroid dependency require supplemental oxygen . Preexisting malignancy . Concurrent Medication : AMENDED : 031991 Prophylaxis antiviral antifungal agent , except PCP prophylaxis prohibit . Drugs metabolize hepatic glucuronidation use caution . Excluded : Prophylaxis oral candidiasis otitis medium infection ( sinusitis , urinary tract infection ) . Immunoglobulin therapy specifically allow . Ketoconazole , acyclovir , nystatin prophylaxis . Drugs metabolize hepatic glucuronidation might alter metabolism zidovudine ( AZT ) . Patients follow exclude : Previous AIDSdefining opportunistic infection neoplasm specify CDC surveillance criterion AIDS . Previous unexplained recurrent , serious bacterial infection ( two within 2year period ) include sepsis , meningitis , pneumonia , abscess internal organ , bone/joint infection cause Haemophilus , Streptococcus , pyogenic bacteria . Qualifying entrance criterion zidovudine ( AZT ) + gammaglobulin ( ACTG 051 ) . Encephalopathy . Failure thrive ( defined child cross two percentile line growth chart child &lt; fifth percentile follow curve ) and/or oral candidiasis least 2 month despite appropriate topical therapy . Lymphocytic interstitial pneumonitis ( LIP ) steroid dependency require supplemental oxygen . Preexisting malignancy . Prior Medication : Excluded within 2 week study entry : Any experimental therapy drug cause prolong neutropenia significant nephrotoxicity . Excluded within 1 month study entry : Antiretroviral agent . Immunomodulating agent include immunoglobulin , interferon , isoprinosine , IL2 . Excluded within 2 month study entry : Systemic ribavirin retroviral therapy . Prior Treatment : Excluded within 1 month study entry : Lymphocyte red blood cell transfusion . Active alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>